Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC)
ASCO 2020 (Virtual)
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients